S-Alpha Therapeutics is a digital therapeutics company developing evidence-based products in areas of high unmet medical need. State-of-the-art technology that combines medical knowledge and cutting-edge software technology is the core engine of the S-Alpha Therapeutics. This synergetic achievement is driven by the cooperation of industry-leading experts in science, medicine, and software engineering. Our goal is to deliver clinically proven products with high efficacy and better therapeutic outcomes.
One of the goals of S-Alpha Therapeutics is to develop digital therapeutics focusing on the areas of big medical unmet need, such as cancer and ophthalmic diseases. One of our leading products in the pipeline, SAT-001 is a novel therapeutic software to treat eye diseases through task-induced interactive experiences.